PCSK9 Inhibitors for the Management of Dyslipidemia in People with Type 2 Diabetes: How Low is Too Low?

Author(s): Ioannis Felekos, Grigoris V. Karamasis, Antonis N. Pavlidis*

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 8 , 2021

Become EABM
Become Reviewer
Call for Editor


Diabetic patients are considered to be at high risk for the development of atherosclerotic disease. Management of hypercholesterolemia is of paramount importance to optimize cardiovascular outcomes in this subset of patients and statins are regarded as the mainstay of treatment. However, the recent advent of PCSK-9 inhibitors has provided a useful alternative in the management of dyslipidemia, especially when statins cannot be tolerated or when hypolipidemic targets cannot be achieved. In this review, we discuss current trends in their use, and we focus on their role in the management of diabetic dyslipidemia.

Keywords: PCSK9 inhibitors, dyslipidemia, diabetes, hypercholesterolemia, atherosclerotic disease, hypolipidemic.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 08 April, 2021
Page: [1008 - 1014]
Pages: 7
DOI: 10.2174/1381612826666200617170252
Price: $65

Article Metrics

PDF: 121